Search results

Lege Artis Medicinae

SEPTEMBER 30, 2020

[Analysis of factors influencing the efficacy of Hungarian acute cardiac care]


[Despite the modern invasive acute cardiac care available for all, as opposed to short-term mortality, the long-term mortality of Hungarian myocardial infarction patients exceeds significantly those of European patients getting similar treatment. In order to change this situation, it is necessary to assess and analyse exactly the factors behind. While analysing retrospectively the data of Hungarian acute myocardial infarction patients, we identified the influencing factors of short- and long-term mortality. This study processed data from 2003 to the present days from a number of registries (Heart- and Vascular Center of Semmelweis University VMAJOR I and VMAJOR II registry, Stent for Life I and II Programs of the European Society of Cardiology, National Public Health Service’s registry about Cardiac Care in Central Hungary, Budapest Modell database). According to our detailed examination, the proportion of primary per­cutaneous coronary intervention in ST-segment elevation myocardial infarction is at Western-European level, however the invasive treatment of acute coronary attack patients with Non-ST segment myocardial infarction is below the required. The so-cal­led hesitation span of Hungarian pa­tients with ST-segment myocardial infarc­tion is substantially longer than that of neighbouring countries thus the average cardiovascular risk of relevant Hungarian patients is significantly higher than those of the GRACE Register’s population. Based on our results a complex strategy can be developed which may have impact also on strategic health­care decisions in order to reduce the long-term mortality of patients surviving myocardial infarction.]

Hypertension and nephrology

SEPTEMBER 10, 2017

[Thought about renovascular hypertension by a special case report]

GAJDÁN Nikolett, LÉGRÁDY Péter, BAJCSI Dóra, MORVAY Zita, NAGY Endre, LETOHA Annamária, KYPROS Constantinou, FEJES Imola, SONKODI Sándor, ÁBRAHÁM György

[Renovascular hypertension is a well-known form of secunder hypertension. Two thirds of cases are caused by atherosclerotic plaque and one third are caused by fibromuscular dysplasia. The prevalence of it is less than 1%. Digital subtraction angiography is considered the goldstandard diagnostic method. The 58-year old female patient was hospitalized with resistant hypertension. Duplex ultrasonography showed fibromuscular stenosis the in left renal artery. Percutaneous transluminal angioplasty and stenting were performed. Her blood pressure normalized. The patient did not attend the control examinations. Next time in 2001, she was referred to our emergency department with increased blood pressure of 210/140 mmHg. Following control ultrasonography angiography showed total occlusion of the left renal artery and significant stenosis of the right renal artery. Left nephrectomy was necessary due to shrunken kidney and dilatation and stenting of the right renal artery. The blood pressure normalized again. Since 2004 until 2014 despite of the regular visits, we detected in stent restenosis of the right renal artery almost in each year. Even so, renal function was preserved all the time. In autumn of 2014, the patient suffered severe stroke, and few months later at the age of 74 she died. There are many open questions to discus concerning the right treatment of renovascular hypertension yet. Even so by performing 12 intravascular interventions we could ensure her acceptable quality of life for 16 years.]

Lege Artis Medicinae

JUNE 01, 2015

[Mechanism of action and role of cilostazol in treatment of peripheral arterial disease]

KOLTAI Katalin, BIRÓ Katalin, KOVÁCS Dávid, CSISZÁR Beáta, TÓTH Kálmán, KÉSMÁRKY Gábor

[Intermittent claudication is a typical symptom of lower extremity arterial disease. Cilostazol is a reversible, selective phosphodiesterase-3 inhibitor which has antiplatelet, antithrombotic and vasodilator effects. It is indicated to improve maximal and pain-free walking distance in patients with intermittent claudication in the absence of rest pain or peripheral tissue necrosis. It can be beneficial in diabetic patiens with intermittent claudication, as it has been proved to prevent the development of foot ulcers. In combination with acetyl-salicylic acid it may help maintain stent patency after endovascular intervention and stent implantation. Cilostazol is contraindicated in heart failure. With cilostazol, a clinically proven effective drug has become available in the treatment of intermittent claudication which could improve walking and life quality of patients.]

Lege Artis Medicinae

JULY 20, 2012

[Use of a drug-eluting stent for the treatment of in-stent restenosis of the superior mesenteric artery]

P. SZABÓ Réka, PÉTER Mózes, VARGA István, VAJDA Gusztáv, HARANGI Mariann, MÁTYUS János, BALLA József

[INTRODUCTION - Diagnosis and treating intestinal ischaemia in time presents a great challenge for clinicians. CASE REPORT - In a 60-year-old woman on dialysis who presented with abdominal angina, angiography revealed stenosis of the superior mesenteric artery, which was treated by implantation of a 6×29 mm Genesis stent. After a year, her symptoms reoccurred and angiography revealed restenosis, which was treated with a 7×34 mm Wallstent, while her previous acetylsalicylic acid treatment was supplemented with clopidrogel. Nevertheless, her abdominal angina reoccurred again after a year. During the next intervention - because of the in-stent restenosis - a Taxus Liberte stent was implanted. During the dual antiplatelet therapy, her abdominal complaints did not reoccur, her body weight increased and angiography did not reveal restenosis in the affected artery even after 4 years. CONCLUSIONS - A drug-eluting stent can be a good choice in case of restenosis of the superior mesenteric artery. In a stented patient, it is crucial to use an appropriately controlled, long-term, dual antiplatelet therapy.]

Lege Artis Medicinae

NOVEMBER 20, 2011

[Perioperative management of patients with coronary stent undergoing noncardiac surgical procedures - Part II. - Algorythm of emergency and perioperative treatment decisions]

ZIMA Endre, MEZŐFI Miklós, BECKER Dávid, SZABÓ György, MERKELY Béla, PÉNZES István

[The aim of percutaneous coronary intervention (PCI) is to optimise coronary and cardial status, and thus improve short- and long-term outcomes. It is known from large Western databases that stent implantation is performed during 77-85% of coronary interventions, which means hundreds of thousands of patients with new stent every year. The majority of patients need to take dual platelet aggregation inhibitor, namely acetyilsalicylic acid and thienopyridin - most often clopidrogel - following stent implantation. It presents a major therapeutic dilemma when these patients need noncardiac surgery. First, the surgery should be performed with the least blood loss possible, which would be optimally achieved by suspension of the platelet aggregation inhibitor therapy that cannot be stopped during the critical period after stent implantation. Second, stent thrombosis should be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current professional guidelines and the current risk estimation in the perioperative management of patients with coronary stent. In the second part of the article, we summarise the preoperative preparation of the patient, assessment of coronary status and cardial medication, and the optimal time and location of the surgery. We present the decision principles regarding the risks of perioperative bleeding and stent thrombosis, and the need to continue platelet aggregation inhibitor therapy.]

Lege Artis Medicinae

OCTOBER 20, 2011

[Perioperative management of patients with coronary stent in case of interventions other than cardiac surgery - Part I. - Perioperative treatment of patients with coronary stent]

ZIMA Endre, MEZŐFI Miklós, BECKER Dávid, SZABÓ György, MERKELY Béla, PÉNZES István

[Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85% of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.]

Hungarian Radiology

APRIL 20, 2003

[Treatment of ureter stenosis of the transplanted kidney using invasive radiological methods]

DOROS Attila, WESZELITS Viola, PUHL Mária, RUSZ András, JANSEN Judit

[INTRODUCTION - Stenosis, occlusion and necrosis of the ureter after kidney transplantation occur in 2-13%. The therapeutic choices are surgery or minimally invasive endourological and percutaneous procedures. We analysed our therapeutic plan and results using percutaneous dilatation and stenting. PATIENTS AND METHODS - The patients after kidney transplantation are regularly examined by ultrasound. In cases of suspected obstruction we perform scintigraphy and CT-urography, and if indicated, we place percutaneous nephrostomy. Between July of 2000 and September of 2002, 15 stenosis in 14 patients were dilated and stented percutaneously. RESULTS - We found one restenosis after 6 months due to compression. This patient underwent surgery, but after the operation another stenosis has developed. We treated it percutaneously. One nephrectomy had to be performed due to serious infection. In one patient stent migration occured and surgical intervention was performed. 12 patients have free urine passage and good kidney function as a result of percutaneous therapy. CONCLUSION - We have good results with percutaneous ureter dilatation and stenting, but our follow-up time (31 months) must be longer for the evaluation of long-term results. The percutaneous treatment can partly replace endourological and surgical methods or can be combined with each other.]

Hungarian Radiology

MARCH 20, 2007

[Transcranial Doppler monitoring of distal embolism during of carotid stenting]


[INTRODUCTION - Reducing the risk of embolisation during endovascular treatment of internal carotid artery stenosis is very important. The rate of embolisation is affected by the different steps of stenting manipulation. Using transcranial Doppler equipment we studied the embolic signals during the different phases of carotid dilatation and stenting. MATERIAL AND METHOD - 50 patients (33 male, 17 female; mean age 64 years) were intraproceduraly monitorized with transcranial Doppler. Predilatation was necessary in nine cases, postdilatation was performed in 39 cases. The number of emboli were measured in seven different steps of endovascular treatment of carotid stenosis. Different type of commercial available endovascular devices were used. RESULTS - Intraprocedural embolisation was observed in every case. In different phases of carotid stenting the rate of embolisation showed marked differences in each phase of carotid stenting. Crossing the stenosis with stent delivery system were accompanied by a low rate of embolism (5.3) compared to the level during stent opening (9.16) and balloon dilatation (9.96). The highest level of embolisation was observed during predilatation (15.9) without the protection of the stent. CONCLUSIONS - We detected embolisation in all of the cases, however the number of embolic signals varied in different phases of carotid artery stenting. Embolisation can be reduced if the most dangerous steps (i.e. pre- and postdilatation) are avoided. Using TCD monitorisation the physician can be informed by the degree of embolisation that may alarm the interventionalist to perform the procedure more carefully, furthermore it can be employed during the training of carotid stenting.]

Lege Artis Medicinae

MARCH 20, 2010

[Examination of the parameters affecting restenosis using coronary stents]


[Treatment of coronary artery stenoses has substantially changed; previous cardiac surgery methods have been replaced by percutaneous coronary interventions, especially coronary stent implantations. Nevertheless, stenonis can reoccur in the artery following stent implantation; this process is called in-stent restenosis. In the present study, we examined the technical characteristics of coronary stents that, if selected optimally, can reduce the frequency of in-stent restenoses. These characteristics include the technology used for the manufacturing of the stent, the stent’s structure, the area of its metal-covered surface, its strut profile and coating. In our study, we examined strut width and profile of ten coronary stents (AVE GFX, Express, Liberté, Multi-Link Zeta, Orbus R, Pro-Kinetic, Sanocor, Tecnic Carbostent, Tentaur, Tentaur-C). We measured strut’s width using an Olympus PMG3 metallurgical microscope, and studied changes of the Sanocor Stent’s strut thickness during the manufacturing process. Our results showed that the Sanocor Stent’s strut thickness was reduced during the manufacturing process.]